

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**ATTY. DOCKET NO.  
1662/53606SERIAL NO.  
10/758,026APPLICANT  
Jean HILDESHEIM et al.FILING DATE  
January 16, 2004GROUP  
Not Yet Assigned**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB- CLASS	FILING DATE*
	4,503,067	March 5, 1985	Wiedemann et al.			
	*5,071,868	December 10, 1991	Herbert Leinert			

\*Copy of reference enclosed.

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 127 099 B1	May 20, 1987	Europe				X
	0 918 055	May 26, 1999	Europe			English Document	
	WO 99/05105	Feb. 4, 1999	PCT			English Document	
	*EP 0 127 099 A	December 5, 1984	Europe			Abstract	

\*Copy of reference enclosed.

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	G.M. Wall, "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No. 2, pages 33-42, February 1986.
	J.K. Haleblian and W. McCrone, "Pharmaceutical Applications of Polymorphism", Journal of Pharmaceutical Sciences, Vol. 58, No. 8, pages 911-929, July 1969.
	J.K. Haleblian, "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications", Journal of Pharmaceutical Sciences, Vol. 64, No. 8, pages 1269-1288, July 1975.
	Pharmacopeial Forum, Vol. 24, No. 1, pages 5438-5441, January - February 1998.
	SENDEROFF et al., "Synthesis of the Enantiomers and Three Racemic Metabolites of Carvedilol Labeled to High Specific Activity With Tritium", Journal of Labeled Compounds and Radiopharmaceuticals, December 1993, Vol. 33, No. 12, pages 1091-1105.
	*Chen, Wei-Min et al. "Synthesis and Crystal Structure of Carvedilol" JIEGOU HUAXUE, Vol. 17, No. 5, Sept. 1998, pages 325-328 (abstract included).
	*Carey, Francis A. et al. "Advanced Organic Chemistry" Third Edition, Part A: Structure and Mechanisms; Plenum Press, pp. 232-239.

\*Copy of reference enclosed.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: 1662/53606	
Application Number 10/758,026	Filing Date January 16, 2004	Examiner Not Yet Assigned	Art Unit Not Yet Assigned
Title CARVEDIOL		Applicant(s) Jean HILDESHEIM et al.	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  
Date: 29 APRIL 2004 Reg. No. 38,413

Signature: \_\_\_\_\_

Joseph A. Coppola

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies are enclosed of each patent, publication or other information listed on the modified PTO Form 1449 marked with an asterisk. Otherwise, copies of each patent, publication or other information listed on the modified PTO Form 1449 are not enclosed since they were previously cited by or submitted to the Patent Office in a prior application, Serial No. 09/894,798, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: APRIL 29, 2004

By: \_\_\_\_\_

Joseph A. Coppola  
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
CUSTOMER NO. 26646